Generalized Anxiety Disorder Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Generalized Anxiety Disorder pipeline constitutes 12+ key companies continuously working towards developing 15+ Generalized Anxiety Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Generalized Anxiety Disorder Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Generalized Anxiety Disorder Market.

The Generalized Anxiety Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Generalized Anxiety Disorder Pipeline Report: https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Generalized Anxiety Disorder treatment therapies with a considerable amount of success over the years.
• Generalized Anxiety Disorder companies working in the treatment market are Fabre-Kramer Pharmaceuticals, Inc., Mind Medicine, Inc., AbbVie, Psy Therapeutics Inc, Pear Therapeutics, Enveric Biosciences, OWP Pharmaceutic, AbbVie, Cybin, Mind Medicine, Inc., Engrail Therapeutics INC, Otsuka Pharmaceutical, Luye PharmaGroup Ltd., and others, are developing therapies for the Generalized Anxiety Disorder treatment
• Emerging Generalized Anxiety Disorder therapies in the different phases of clinical trials are- EXXUA, MM120, ABBV-932, PSY-05, Pear-011, EVM201 Series, Duloxetine Hydrochloride , ABBV 932, CYB004, MM-120, ENX-102, Ulotaront, LY03005, and others are expected to have a significant impact on the Generalized Anxiety Disorder market in the coming years.
• In February 2025, MindMed's Chief Medical Officer, Daniel Karlin, MD, MA, announced the initiation of Panorama (MM120-301), the second Phase 3 trial evaluating MM120 (lysergide D-tartrate) for generalized anxiety disorder (GAD). This follows Voyage (MM120-300), the first-ever Phase 3 study of LSD for any medical condition, which was a two-arm, placebo-controlled trial conducted in the US over 12 weeks using 100 micrograms of MM120. Panorama expands the study by adding a 50-microgram dose arm and extending recruitment to both the US and EU. The lower dose aims to better assess the drug's effects while minimizing functional unblinding, where participants might guess their treatment based on perceptual experiences.
• In January 2025, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company focused on developing innovative treatments for brain health disorders, has announced the dosing of the first patient in its Panorama study. This is the company's second Phase 3 study evaluating MM120 ODT, a specialized form of LSD, for the treatment of generalized anxiety disorder (GAD). The study, which will assess the efficacy and safety of MM120 ODT compared to a placebo, will be conducted in the United States and Europe, with an estimated 250 participants
• In June 2024, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on developing innovative treatments for brain health disorders, has announced the successful completion of its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). This meeting supports the progression of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with generalized anxiety disorder (GAD).
• In March 2024, Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company specializing in advancing both traditional and innovative behavioral health treatments with a commitment to safe, evidence-based therapies, extends congratulations to Mind Medicine ("MindMed" NASDAQ: MNMD, Cboe Canada: MMED) on the positive outcomes of its Phase 2b clinical trial evaluating MM120 (lysergide d-tartrate) for generalized anxiety disorder ("GAD"). Results indicated that four weeks following a single 100-microgram dose of MM120, 48 percent of participants achieved remission with no clinically significant anxiety, and 65 percent experienced clinically meaningful improvement. Given the promising initial clinical findings and recognizing the substantial unmet medical need in treating GAD, the U.S. Food & Drug Administration ("FDA") has granted MM120 for GAD a breakthrough therapy designation.
• In February 2024, Incannex Healthcare Inc. (Nasdaq: IXHL), a prominent biotechnology company specializing in cannabinid and psychedelic medicine, is excited to share positive topline results from its Phase 2 Psi-GAD1 clinical trial evaluating psilocybin for generalized anxiety disorder (GAD). The trial successfully met its primary endpoint, showing a significant clinical effect in the psilocybin treatment group compared to the placebo group.

Generalized Anxiety Disorder Overview
Generalized Anxiety Disorder (GAD) is a mental health condition characterized by persistent and excessive worry about various aspects of daily life, such as work, health, relationships, and other personal issues. Individuals with GAD often find it difficult to control their anxiety, which can lead to physical symptoms like restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbances. The anxiety experienced is disproportionate to the actual situation, significantly impacting the person's daily functioning and quality of life. Treatment options include psychotherapy, medication, and lifestyle changes aimed at managing anxiety symptoms.

Get a Free Sample PDF Report to know more about Generalized Anxiety Disorder Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/generalized-anxiety-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Generalized Anxiety Disorder Drugs Under Different Phases of Clinical Development Include:
• EXXUA: Fabre-Kramer Pharmaceuticals, Inc.
• MM120: Mind Medicine, Inc.
• ABBV-932: AbbVie
• PSY-05: Psy Therapeutics Inc
• Pear-011: Pear Therapeutics
• EVM201 Series: Enveric Biosciences
• Duloxetine Hydrochloride : OWP Pharmaceutic als
• ABBV 932: AbbVie
• CYB004: Cybin
• MM-120: Mind Medicine, Inc.
• ENX-102: Engrail Therapeutics INC
• Ulotaront: Otsuka Pharmaceutical
• LY03005: Luye PharmaGroup Ltd.

Generalized Anxiety Disorder Route of Administration
Generalized Anxiety Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous
• Oral
• Intramuscular

Generalized Anxiety Disorder Molecule Type
Generalized Anxiety Disorder Products have been categorized under various Molecule types, such as
• Small molecules
• Peptides

Generalized Anxiety Disorder Pipeline Therapeutics Assessment
• Generalized Anxiety Disorder Assessment by Product Type
• Generalized Anxiety Disorder By Stage and Product Type
• Generalized Anxiety Disorder Assessment by Route of Administration
• Generalized Anxiety Disorder By Stage and Route of Administration
• Generalized Anxiety Disorder Assessment by Molecule Type
• Generalized Anxiety Disorder by Stage and Molecule Type

DelveInsight's Generalized Anxiety Disorder Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Generalized Anxiety Disorder product details are provided in the report. Download the Generalized Anxiety Disorder pipeline report to learn more about the emerging Generalized Anxiety Disorder therapies at:
https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Generalized Anxiety Disorder Therapeutics Market include:
Key companies developing therapies for Generalized Anxiety Disorder are - Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, MindMed, VistaGen Pharma, Actavis, Takeda Pharma, Bionomics, GSK, Pfizer, Bristol-Myers Squibb, Actavis Pharma, and others.

Generalized Anxiety Disorder Pipeline Analysis:
The Generalized Anxiety Disorder pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Generalized Anxiety Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Generalized Anxiety Disorder Treatment.
• Generalized Anxiety Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Generalized Anxiety Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Generalized Anxiety Disorder market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Generalized Anxiety Disorder drugs and therapies-
https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Generalized Anxiety Disorder Pipeline Market Drivers
• Soaring Applications of Cognitive Behavioral Therapy for Generalized Anxiety Disorder are Expected to Boost the Growth, increasing Predominance of Generalized Anxiety Disorder are some of the important factors that are fueling the Generalized Anxiety Disorder Market.

Generalized Anxiety Disorder Pipeline Market Barriers
• However, poor diagnosis rate of generalized anxiety disorder owing to the lack of a suitable diagnosis test, limited access to mental health services and other factors are creating obstacles in the Generalized Anxiety Disorder Market growth.

Scope of Generalized Anxiety Disorder Pipeline Drug Insight
• Coverage: Global
• Key Generalized Anxiety Disorder Companies: Fabre-Kramer Pharmaceuticals, Inc., Mind Medicine, Inc., AbbVie, Psy Therapeutics Inc, Pear Therapeutics, Enveric Biosciences, OWP Pharmaceutic als, AbbVie, Cybin, Mind Medicine, Inc., Engrail Therapeutics INC, Otsuka Pharmaceutical, Luye PharmaGroup Ltd., and others
• Key Generalized Anxiety Disorder Therapies: EXXUA, MM120, ABBV-932, PSY-05, Pear-011, EVM201 Series, Duloxetine Hydrochloride , ABBV 932, CYB004, MM-120, ENX-102, Ulotaront, LY03005, and others
• Generalized Anxiety Disorder Therapeutic Assessment: Generalized Anxiety Disorder current marketed and Generalized Anxiety Disorder emerging therapies
• Generalized Anxiety Disorder Market Dynamics: Generalized Anxiety Disorder market drivers and Generalized Anxiety Disorder market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.